Infertility Treatment Market by Product Type (Accessories, Equipment, Media & Consumables), Treatment Type (Artificial Insemination, Assisted Reproductive Technology (ART), Fertility Drugs), Diagnosis, End User - Global Forecast 2025-2032
Description
The Infertility Treatment Market was valued at USD 5.93 billion in 2024 and is projected to grow to USD 6.58 billion in 2025, with a CAGR of 11.61%, reaching USD 14.30 billion by 2032.
Setting the Stage for a Comprehensive Examination of the Global Infertility Treatment Landscape and Its Emerging Dynamics
Understanding the multifaceted nature of infertility requires a thorough exploration of biological, technological, and socioeconomic factors that influence patient outcomes. As prevalence rates continue to climb, driven by delayed parenthood, environmental factors, and lifestyle changes, healthcare providers and technology innovators face mounting pressure to develop more effective and accessible solutions. This report delves into the intricate ecosystem of infertility treatment, examining how equipment, consumables, and procedural methodologies converge to drive patient success.
This introduction establishes the foundation for an in-depth analysis of emerging dynamics shaping the global infertility treatment market. It outlines the scope of investigation, highlights key themes such as technological innovation and regulatory evolution, and sets expectations for the detailed insights presented in subsequent sections. By framing the discussion around critical drivers and challenges, this segment prepares decision makers to navigate a landscape marked by rapid change and strategic differentiation.
Uncovering the Forces Driving Fundamental Changes in Infertility Treatment Modalities and Patient Pathways Across the Healthcare Ecosystem
Advancements in personalized medicine and digital health are reshaping how infertility treatments are conceived and delivered. Patients now expect tailored care pathways that leverage genetic screening, data analytics, and remote monitoring to optimize outcomes. Simultaneously, the integration of artificial intelligence into embryology labs and predictive modeling tools is accelerating time to pregnancy and improving success rates. These shifts underscore a move away from one-size-fits-all protocols toward bespoke interventions guided by real-time insights.
Regulatory bodies and payers are also adapting to this new paradigm, introducing frameworks that incentivize evidence-based innovation and patient-centered approaches. As telehealth platforms expand and consolidate, the boundaries between in-clinic procedures and virtual care blur, leading to interdisciplinary collaborations among reproductive endocrinologists, genetic counselors, and digital therapeutics providers. Such collaborative networks are critical for addressing cost pressures and ensuring equitable access to advanced treatment modalities across diverse patient populations.
Analyzing the Cumulative Effects of United States Tariff Adjustments on the Infertility Treatment Market Throughout the Year Twenty Twenty Five
Recent tariff adjustments imposed by the United States on imported medical devices and laboratory equipment have introduced both challenges and opportunities for stakeholders in the infertility treatment market. Increased duties on critical components, including imaging systems and cryopreservation media, have prompted suppliers to reevaluate supply chain strategies. In response, many manufacturers are exploring near-shoring or diversified sourcing to mitigate cost pressures while maintaining quality and compliance with stringent regulatory standards.
These shifts are catalyzing innovation in product design and manufacturing. Equipment providers are accelerating the development of modular systems that local partners can assemble, reducing exposure to cross-border fees. At the same time, consumables suppliers are investing in formulation advancements that extend shelf life and lower freight sensitivity. Although short-term cost pass-through to clinics remains a concern, the long-term effect may be a more resilient ecosystem characterized by regional manufacturing clusters and enhanced supply-chain transparency.
Deciphering Key Segmentation Patterns by Product Type Treatment Type Diagnosis and End User Revealing Critical Market Differentiators
An examination of segmentation reveals how diverse product categories drive targeted innovations and competitive positioning. Equipment, encompassing cryosystems, gas analyzers, imaging systems, incubators, laser technologies, micromanipulators, and analytical devices, remains at the forefront of R&D investment. Media & consumables, including cryopreservation formulations and culture solutions, underpin critical procedural success. Accessories, while often overlooked, are gaining traction through ergonomic design improvements and single-use disposables that streamline workflow and enhance sterility.
Treatment type segmentation further highlights the spectrum of clinical interventions, from artificial insemination techniques spanning intracervical, intratubal, and intrauterine options, to advanced assisted reproductive technologies such as embryo cryopreservation, in vitro fertilization protocols, intracytoplasmic sperm injection, and preimplantation genetic diagnosis. Pharmacological therapies leverage clomiphene citrate, gonadotropins, letrozole, and metformin to stimulate ovulation, while surgical procedures including hysteroscopy, laparoscopy, myomectomy, varicocele repair, and varicocelectomy address anatomical barriers. Diagnostic methodologies split between female-focused hysterosalpingography and ovulation testing and male-oriented blood analyses, semen evaluations, and testicular biopsies. Across these segments, end users ranging from cryobanks and fertility clinics to hospitals and research institutes establish distinct service models, reflecting varied operational scales and patient demographics.
Illuminating Regional Variations in Infertility Treatment Demand and Service Adoption Across the Americas Europe Middle East Africa and Asia Pacific
Regional analysis underscores how geographic and cultural nuances influence service adoption and technology deployment. In the Americas, robust reimbursement frameworks and advanced clinical infrastructure drive early adoption of cutting-edge equipment and digital platforms. Leading fertility clinics collaborate with academic centers to pioneer clinical trials, while cryobanks refine preservation protocols to support growing demand for donor gametes.
In Europe, Middle East and Africa, regulatory harmonization efforts across the European Union and emerging healthcare reforms in select Middle Eastern markets have spurred investment in assisted reproductive technologies. Research institutes collaborate with regional laboratories to validate locally relevant culture media and diagnostic assays. Meanwhile, in the Asia Pacific region, rapid economic growth, expanding middle-class populations, and supportive government initiatives are fueling the expansion of fertility clinics. Local manufacturers are scaling up production of incubators and analyzers, catering to rising patient volumes and cost-sensitive market segments.
Unveiling Strategic Movements and Competitive Positioning Among Leading Entities in the Global Infertility Treatment Arena for Informed Decision Making
Analysis of leading players in the infertility treatment market reveals diverse strategic approaches to capture growth opportunities. Equipment manufacturers are forming alliances with biotechnology firms to integrate novel imaging modalities and automation into existing product portfolios. Pharmaceutical companies, recognizing the importance of personalized medicine, are partnering with diagnostic specialists to co-develop companion assays that guide fertility drug selection and dosing.
Meanwhile, clinical service providers and cryobank operators are consolidating through mergers and joint ventures to achieve scale, standardize best practices, and expand geographic reach. Research institutes and technology startups are bridging innovation gaps by licensing proprietary culture media formulations and AI-driven lab software to established brands. This collaborative ecosystem is accelerating time-to-market for breakthrough solutions while ensuring robust regulatory compliance and streamlined distribution channels.
Formulating Actionable Strategies to Enhance Market Positioning Drive Innovation and Address Critical Challenges in Fertility Care Delivery
To capitalize on evolving market dynamics, industry leaders should prioritize end-to-end digital integration that enhances patient engagement and clinical efficiency. Investing in predictive analytics platforms and telehealth interfaces can streamline patient journeys from initial diagnosis through post-procedure monitoring, while reducing administrative overhead. Additionally, diversifying product offerings to include single-use consumables and modular equipment designs can improve operational resilience against supply-chain disruptions.
Collaboration with regulatory bodies and payer organizations is critical for shaping reimbursement models that reward outcome-based care. Establishing cross-sector partnerships with genetic testing labs, software developers, and fertility specialists will foster co-innovation and accelerate adoption of advanced protocols. Finally, expanding presence in high-growth regions through localized manufacturing and strategic alliances can unlock new patient segments and ensure sustainable growth trajectories.
Explaining a Robust Research Methodology Integrating Multi Source Data Collection Analytical Frameworks and Validation Techniques for Market Credibility
This research synthesizes insights from a multi-stage process beginning with an exhaustive review of publicly available literature, regulatory filings, and patent databases. In parallel, primary interviews were conducted with a cross-section of stakeholders, including clinical directors, lab managers, equipment engineers, and policy experts. These qualitative inputs were triangulated with quantitative performance indicators to validate trends and identify emerging inflection points.
An analytical framework was applied to assess market maturity, competitive intensity, and technology diffusion across segments. Data modeling techniques incorporated scenario planning to evaluate tariff impacts and regulatory changes. Finally, an internal peer-review session ensured methodological rigor, with an emphasis on replicability and transparency. This comprehensive approach underpins the credibility of findings and supports confident decision making.
Concluding Insights That Synthesize Market Dynamics Strategic Imperatives and Future Opportunities in the Infertility Treatment Sector
The insights presented throughout this executive summary illuminate the transformative forces at play in the infertility treatment sector. Technological advancements, coupled with shifting regulatory landscapes and evolving patient expectations, are creating unprecedented opportunities for innovation and collaboration. Organizations that embrace data-driven decision making and agile operational models will be best positioned to lead this dynamic marketplace.
As the industry continues to mature, the ability to integrate personalized therapies, optimize supply chains, and navigate cross-border considerations will define competitive advantage. By synthesizing segmentation, regional, and competitive insights, stakeholders can refine strategic roadmaps and allocate resources toward high-impact initiatives. The conclusion underscores the imperative for continual adaptation and foresight in order to drive sustainable growth and enhance patient outcomes.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Accessories
Equipment
Cryosystems
Gas Analyzers
Imaging Systems
Incubators
Laser Systems
Micromanipulator Systems
Microscopes
Ovum Aspiration Pumps
Sperm Analyzer Systems
Sperm Separation Devices
Media & Consumables
Cryopreservation Media
Culture Media
Treatment Type
Artificial Insemination
Intracervical Insemination
Intratubal Insemination
Intrauterine Insemination
Assisted Reproductive Technology (ART)
Embryo Cryopreservation
In Vitro Fertilization (IVF)
Intracytoplasmic Sperm Injection (ICSI)
Preimplantation Genetic Diagnosis (PGD)
Fertility Drugs
Clomiphene Citrate
Gonadotropins
Letrozole
Metformin
Fertility Surgeries
Hysteroscopy
Laparoscopy
Myomectomy
Varicocele Repair
Varicocelectomy
Diagnosis
Female Infertility
Hysterosalpingography (HSG)
Ovulation Testing
Male Infertility
Blood Tests
Semen Analysis
Testicular Biopsy
End User
Cryobanks
Fertility Clinics
Hospitals
Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Bayer AG
City Fertility Centre
CooperSurgical, Inc.
Cryoport Systems, LLC.
Embryolab
Ferring International Center S.A.
FUJIFILM Irvine Scientific, Inc.
Genea Group
IVI AMERICA, LLC
Merck KGaA
Monash IVF
New Hope Fertility Clinic
Nova IVF Fertility
NOW-fertility SA
Ovum Woman and Child specialty Hospital
ReproTech LLC
Seegene, Inc.
TMRW Life Sciences, Inc.
Vitrolife Sweden AB
Please Note: PDF & Excel + Online Access - 1 Year
Setting the Stage for a Comprehensive Examination of the Global Infertility Treatment Landscape and Its Emerging Dynamics
Understanding the multifaceted nature of infertility requires a thorough exploration of biological, technological, and socioeconomic factors that influence patient outcomes. As prevalence rates continue to climb, driven by delayed parenthood, environmental factors, and lifestyle changes, healthcare providers and technology innovators face mounting pressure to develop more effective and accessible solutions. This report delves into the intricate ecosystem of infertility treatment, examining how equipment, consumables, and procedural methodologies converge to drive patient success.
This introduction establishes the foundation for an in-depth analysis of emerging dynamics shaping the global infertility treatment market. It outlines the scope of investigation, highlights key themes such as technological innovation and regulatory evolution, and sets expectations for the detailed insights presented in subsequent sections. By framing the discussion around critical drivers and challenges, this segment prepares decision makers to navigate a landscape marked by rapid change and strategic differentiation.
Uncovering the Forces Driving Fundamental Changes in Infertility Treatment Modalities and Patient Pathways Across the Healthcare Ecosystem
Advancements in personalized medicine and digital health are reshaping how infertility treatments are conceived and delivered. Patients now expect tailored care pathways that leverage genetic screening, data analytics, and remote monitoring to optimize outcomes. Simultaneously, the integration of artificial intelligence into embryology labs and predictive modeling tools is accelerating time to pregnancy and improving success rates. These shifts underscore a move away from one-size-fits-all protocols toward bespoke interventions guided by real-time insights.
Regulatory bodies and payers are also adapting to this new paradigm, introducing frameworks that incentivize evidence-based innovation and patient-centered approaches. As telehealth platforms expand and consolidate, the boundaries between in-clinic procedures and virtual care blur, leading to interdisciplinary collaborations among reproductive endocrinologists, genetic counselors, and digital therapeutics providers. Such collaborative networks are critical for addressing cost pressures and ensuring equitable access to advanced treatment modalities across diverse patient populations.
Analyzing the Cumulative Effects of United States Tariff Adjustments on the Infertility Treatment Market Throughout the Year Twenty Twenty Five
Recent tariff adjustments imposed by the United States on imported medical devices and laboratory equipment have introduced both challenges and opportunities for stakeholders in the infertility treatment market. Increased duties on critical components, including imaging systems and cryopreservation media, have prompted suppliers to reevaluate supply chain strategies. In response, many manufacturers are exploring near-shoring or diversified sourcing to mitigate cost pressures while maintaining quality and compliance with stringent regulatory standards.
These shifts are catalyzing innovation in product design and manufacturing. Equipment providers are accelerating the development of modular systems that local partners can assemble, reducing exposure to cross-border fees. At the same time, consumables suppliers are investing in formulation advancements that extend shelf life and lower freight sensitivity. Although short-term cost pass-through to clinics remains a concern, the long-term effect may be a more resilient ecosystem characterized by regional manufacturing clusters and enhanced supply-chain transparency.
Deciphering Key Segmentation Patterns by Product Type Treatment Type Diagnosis and End User Revealing Critical Market Differentiators
An examination of segmentation reveals how diverse product categories drive targeted innovations and competitive positioning. Equipment, encompassing cryosystems, gas analyzers, imaging systems, incubators, laser technologies, micromanipulators, and analytical devices, remains at the forefront of R&D investment. Media & consumables, including cryopreservation formulations and culture solutions, underpin critical procedural success. Accessories, while often overlooked, are gaining traction through ergonomic design improvements and single-use disposables that streamline workflow and enhance sterility.
Treatment type segmentation further highlights the spectrum of clinical interventions, from artificial insemination techniques spanning intracervical, intratubal, and intrauterine options, to advanced assisted reproductive technologies such as embryo cryopreservation, in vitro fertilization protocols, intracytoplasmic sperm injection, and preimplantation genetic diagnosis. Pharmacological therapies leverage clomiphene citrate, gonadotropins, letrozole, and metformin to stimulate ovulation, while surgical procedures including hysteroscopy, laparoscopy, myomectomy, varicocele repair, and varicocelectomy address anatomical barriers. Diagnostic methodologies split between female-focused hysterosalpingography and ovulation testing and male-oriented blood analyses, semen evaluations, and testicular biopsies. Across these segments, end users ranging from cryobanks and fertility clinics to hospitals and research institutes establish distinct service models, reflecting varied operational scales and patient demographics.
Illuminating Regional Variations in Infertility Treatment Demand and Service Adoption Across the Americas Europe Middle East Africa and Asia Pacific
Regional analysis underscores how geographic and cultural nuances influence service adoption and technology deployment. In the Americas, robust reimbursement frameworks and advanced clinical infrastructure drive early adoption of cutting-edge equipment and digital platforms. Leading fertility clinics collaborate with academic centers to pioneer clinical trials, while cryobanks refine preservation protocols to support growing demand for donor gametes.
In Europe, Middle East and Africa, regulatory harmonization efforts across the European Union and emerging healthcare reforms in select Middle Eastern markets have spurred investment in assisted reproductive technologies. Research institutes collaborate with regional laboratories to validate locally relevant culture media and diagnostic assays. Meanwhile, in the Asia Pacific region, rapid economic growth, expanding middle-class populations, and supportive government initiatives are fueling the expansion of fertility clinics. Local manufacturers are scaling up production of incubators and analyzers, catering to rising patient volumes and cost-sensitive market segments.
Unveiling Strategic Movements and Competitive Positioning Among Leading Entities in the Global Infertility Treatment Arena for Informed Decision Making
Analysis of leading players in the infertility treatment market reveals diverse strategic approaches to capture growth opportunities. Equipment manufacturers are forming alliances with biotechnology firms to integrate novel imaging modalities and automation into existing product portfolios. Pharmaceutical companies, recognizing the importance of personalized medicine, are partnering with diagnostic specialists to co-develop companion assays that guide fertility drug selection and dosing.
Meanwhile, clinical service providers and cryobank operators are consolidating through mergers and joint ventures to achieve scale, standardize best practices, and expand geographic reach. Research institutes and technology startups are bridging innovation gaps by licensing proprietary culture media formulations and AI-driven lab software to established brands. This collaborative ecosystem is accelerating time-to-market for breakthrough solutions while ensuring robust regulatory compliance and streamlined distribution channels.
Formulating Actionable Strategies to Enhance Market Positioning Drive Innovation and Address Critical Challenges in Fertility Care Delivery
To capitalize on evolving market dynamics, industry leaders should prioritize end-to-end digital integration that enhances patient engagement and clinical efficiency. Investing in predictive analytics platforms and telehealth interfaces can streamline patient journeys from initial diagnosis through post-procedure monitoring, while reducing administrative overhead. Additionally, diversifying product offerings to include single-use consumables and modular equipment designs can improve operational resilience against supply-chain disruptions.
Collaboration with regulatory bodies and payer organizations is critical for shaping reimbursement models that reward outcome-based care. Establishing cross-sector partnerships with genetic testing labs, software developers, and fertility specialists will foster co-innovation and accelerate adoption of advanced protocols. Finally, expanding presence in high-growth regions through localized manufacturing and strategic alliances can unlock new patient segments and ensure sustainable growth trajectories.
Explaining a Robust Research Methodology Integrating Multi Source Data Collection Analytical Frameworks and Validation Techniques for Market Credibility
This research synthesizes insights from a multi-stage process beginning with an exhaustive review of publicly available literature, regulatory filings, and patent databases. In parallel, primary interviews were conducted with a cross-section of stakeholders, including clinical directors, lab managers, equipment engineers, and policy experts. These qualitative inputs were triangulated with quantitative performance indicators to validate trends and identify emerging inflection points.
An analytical framework was applied to assess market maturity, competitive intensity, and technology diffusion across segments. Data modeling techniques incorporated scenario planning to evaluate tariff impacts and regulatory changes. Finally, an internal peer-review session ensured methodological rigor, with an emphasis on replicability and transparency. This comprehensive approach underpins the credibility of findings and supports confident decision making.
Concluding Insights That Synthesize Market Dynamics Strategic Imperatives and Future Opportunities in the Infertility Treatment Sector
The insights presented throughout this executive summary illuminate the transformative forces at play in the infertility treatment sector. Technological advancements, coupled with shifting regulatory landscapes and evolving patient expectations, are creating unprecedented opportunities for innovation and collaboration. Organizations that embrace data-driven decision making and agile operational models will be best positioned to lead this dynamic marketplace.
As the industry continues to mature, the ability to integrate personalized therapies, optimize supply chains, and navigate cross-border considerations will define competitive advantage. By synthesizing segmentation, regional, and competitive insights, stakeholders can refine strategic roadmaps and allocate resources toward high-impact initiatives. The conclusion underscores the imperative for continual adaptation and foresight in order to drive sustainable growth and enhance patient outcomes.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Accessories
Equipment
Cryosystems
Gas Analyzers
Imaging Systems
Incubators
Laser Systems
Micromanipulator Systems
Microscopes
Ovum Aspiration Pumps
Sperm Analyzer Systems
Sperm Separation Devices
Media & Consumables
Cryopreservation Media
Culture Media
Treatment Type
Artificial Insemination
Intracervical Insemination
Intratubal Insemination
Intrauterine Insemination
Assisted Reproductive Technology (ART)
Embryo Cryopreservation
In Vitro Fertilization (IVF)
Intracytoplasmic Sperm Injection (ICSI)
Preimplantation Genetic Diagnosis (PGD)
Fertility Drugs
Clomiphene Citrate
Gonadotropins
Letrozole
Metformin
Fertility Surgeries
Hysteroscopy
Laparoscopy
Myomectomy
Varicocele Repair
Varicocelectomy
Diagnosis
Female Infertility
Hysterosalpingography (HSG)
Ovulation Testing
Male Infertility
Blood Tests
Semen Analysis
Testicular Biopsy
End User
Cryobanks
Fertility Clinics
Hospitals
Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Bayer AG
City Fertility Centre
CooperSurgical, Inc.
Cryoport Systems, LLC.
Embryolab
Ferring International Center S.A.
FUJIFILM Irvine Scientific, Inc.
Genea Group
IVI AMERICA, LLC
Merck KGaA
Monash IVF
New Hope Fertility Clinic
Nova IVF Fertility
NOW-fertility SA
Ovum Woman and Child specialty Hospital
ReproTech LLC
Seegene, Inc.
TMRW Life Sciences, Inc.
Vitrolife Sweden AB
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of personalized genetic screening to improve IVF success rates and reduce treatment cycles
- 5.2. Development of noninvasive fertility monitoring devices using wearable sensor technology for real time ovulation tracking
- 5.3. Expansion of fertility preservation services for cancer patients combining cryopreservation with oncofertility counseling
- 5.4. Integration of artificial intelligence in embryo selection processes to enhance implantation rates in IVF clinics
- 5.5. Rising collaborations between fertility clinics and telehealth platforms to increase remote patient access and support
- 5.6. Surge in demand for egg and sperm donor banking driven by social fertility planning and single parenthood trends
- 5.7. Emergence of at home hormone testing kits offering cost effective alternatives to traditional clinical assessments
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Infertility Treatment Market, by Product Type
- 8.1. Accessories
- 8.2. Equipment
- 8.2.1. Cryosystems
- 8.2.2. Gas Analyzers
- 8.2.3. Imaging Systems
- 8.2.4. Incubators
- 8.2.5. Laser Systems
- 8.2.6. Micromanipulator Systems
- 8.2.7. Microscopes
- 8.2.8. Ovum Aspiration Pumps
- 8.2.9. Sperm Analyzer Systems
- 8.2.10. Sperm Separation Devices
- 8.3. Media & Consumables
- 8.3.1. Cryopreservation Media
- 8.3.2. Culture Media
- 9. Infertility Treatment Market, by Treatment Type
- 9.1. Artificial Insemination
- 9.1.1. Intracervical Insemination
- 9.1.2. Intratubal Insemination
- 9.1.3. Intrauterine Insemination
- 9.2. Assisted Reproductive Technology (ART)
- 9.2.1. Embryo Cryopreservation
- 9.2.2. In Vitro Fertilization (IVF)
- 9.2.3. Intracytoplasmic Sperm Injection (ICSI)
- 9.2.4. Preimplantation Genetic Diagnosis (PGD)
- 9.3. Fertility Drugs
- 9.3.1. Clomiphene Citrate
- 9.3.2. Gonadotropins
- 9.3.3. Letrozole
- 9.3.4. Metformin
- 9.4. Fertility Surgeries
- 9.4.1. Hysteroscopy
- 9.4.2. Laparoscopy
- 9.4.3. Myomectomy
- 9.4.4. Varicocele Repair
- 9.4.5. Varicocelectomy
- 10. Infertility Treatment Market, by Diagnosis
- 10.1. Female Infertility
- 10.1.1. Hysterosalpingography (HSG)
- 10.1.2. Ovulation Testing
- 10.2. Male Infertility
- 10.2.1. Blood Tests
- 10.2.2. Semen Analysis
- 10.2.3. Testicular Biopsy
- 11. Infertility Treatment Market, by End User
- 11.1. Cryobanks
- 11.2. Fertility Clinics
- 11.3. Hospitals
- 11.4. Research Institutes
- 12. Infertility Treatment Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Infertility Treatment Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Infertility Treatment Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Bayer AG
- 15.3.2. City Fertility Centre
- 15.3.3. CooperSurgical, Inc.
- 15.3.4. Cryoport Systems, LLC.
- 15.3.5. Embryolab
- 15.3.6. Ferring International Center S.A.
- 15.3.7. FUJIFILM Irvine Scientific, Inc.
- 15.3.8. Genea Group
- 15.3.9. IVI AMERICA, LLC
- 15.3.10. Merck KGaA
- 15.3.11. Monash IVF
- 15.3.12. New Hope Fertility Clinic
- 15.3.13. Nova IVF Fertility
- 15.3.14. NOW-fertility SA
- 15.3.15. Ovum Woman and Child specialty Hospital
- 15.3.16. ReproTech LLC
- 15.3.17. Seegene, Inc.
- 15.3.18. TMRW Life Sciences, Inc.
- 15.3.19. Vitrolife Sweden AB
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
